Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1133
Abstract: The pharmacokinetics (PK) and safety of ofatumumab and bendamustine alone and in combination were evaluated in patients with treatment‐naive or relapsed indolent B‐cell non‐Hodgkin lymphoma (iNHL). Patients were randomly assigned to ofatumumab and bendamustine or… read more here.
Keywords: hodgkin lymphoma; non hodgkin; indolent cell; concentration ... See more keywords
Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B‐cell lymphomas
Sign Up to like & getrecommendations! Published in 2021 at "Hematological Oncology"
DOI: 10.1002/hon.2871
Abstract: Bendamusutine plus rituximab (BR) regimen is one of the standard regimens for indolent B‐cell lymphomas, yet the possibility of reduction of cycles of BR therapy without compromising therapeutic effects is not still uncovered. We retrospectively… read more here.
Keywords: response; indolent cell; cell lymphomas; reduction cycles ... See more keywords
Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-02908-8
Abstract: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is one of the standard regimens for indolent B-cell non-Hodgkin’s lymphoma (NHL). It is unclear whether the prednisolone (PSL) dosage affects the therapeutic effect or the adverse… read more here.
Keywords: indolent cell; psl day; prednisolone; dosage ... See more keywords
BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Chemotherapy"
DOI: 10.1080/1120009x.2022.2043512
Abstract: Abstract Bendamustine plus rituximab (BR) and rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) have been shown to be effective in the treatment of indolent B-cell lymphomas (iBCL). The survival outcomes and adverse events of BR… read more here.
Keywords: meta analysis; chop; plus rituximab; indolent cell ... See more keywords
Indolent NK-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract - a Report of two Cases of a new Provisional Entity on the World Health Organization Classification of Hematolymphoid Tumors.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of surgical pathology"
DOI: 10.1177/10668969221113474
Abstract: Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract is a new provisional entity listed in the structure of the forthcoming fifth edition of the World Health Organization (WHO) Classification of Hematolymphoid Tumors. It was first… read more here.
Keywords: cell; entity; cell lymphoproliferative; indolent cell ... See more keywords
Efficacy of Yttrium-90 Iburitumomab Tiuxetan for Early Relapsed/Refractory Indolent B-Cell Lymphoma: A Single Institute Retrospective Analysis in the Rituximab Era
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-112782
Abstract: Introduction: Indolent B-cell lymphoma is a type of non-Hodgkin's lymphoma that grows slowly and is not a curative disease. Yttrium-90 (90Y) iburitumomab tiuxetan is used in patients with relapsed/refractory indolent B-cell lymphoma, data is still… read more here.
Keywords: 90y iburitumomab; indolent cell; iburitumomab tiuxetan; cell ... See more keywords
Extensive involvement of indolent T-cell lymphoma in a patient with ulcerative colitis.
Sign Up to like & getrecommendations! Published in 2023 at "Revista espanola de enfermedades digestivas"
DOI: 10.17235/reed.2023.9623/2023
Abstract: Indolent T-cell lymphoma is a rare disease. Here we presented a 53-year-old male patient initially diagnosed as ulcerative colitis in 2000 that finally developed into extensive indolent T-cell lymphoma in 2022. We also described the differences… read more here.
Keywords: cell lymphoma; indolent cell; ulcerative colitis;
Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.3324/haematol.2019.230961
Abstract: Indolent T-cell lymphoproliferative disorders of the gastrointestinal tract are rare clonal T-cell diseases that more commonly occur in the intestines and have a protracted clinical course. Different immunophenotypic subsets have been described, but the molecular… read more here.
Keywords: cell lymphoproliferative; cd4 cd8; indolent cell; lymphoproliferative disorders ... See more keywords
Indolent T-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract (iTLPD-GI): A Review
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13112790
Abstract: Simple Summary This review aims to better define the clinical, pathological, and molecular features of the novel lymphoproliferative disease termed “indolent T-cell lymphoproliferative disorder of the gastro-intestinal tract (iTLPD-GI)”, to discuss potential pitfalls in differentiating… read more here.
Keywords: cell lymphoproliferative; indolent cell; tract; review ... See more keywords
How We Manage Patients with Indolent B-Cell Malignancies on Bruton’s Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists
Sign Up to like & getrecommendations! Published in 2023 at "Current Oncology"
DOI: 10.3390/curroncol30040322
Abstract: The most common forms of B-cell malignancy, non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), have seen a drastic shift in the treatment landscape over the last two decades with the introduction of targeted agents.… read more here.
Keywords: bruton tyrosine; indolent cell; btk; tyrosine kinase ... See more keywords